Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dornan

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Blood|July 28, 2009
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphomaDavid Dornan, Fiona Bennett, Yvonne Chen, et al.
Science Signaling|June 16, 2011
TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Science Signaling|August 27, 2011
miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Blood|August 14, 2010
Effect of FCGR2A and FCGR3A variants on CLL outcomeDavid Dornan, Olivia Spleiss, Ru-Fang Yeh, et al.
Molecular Cancer Therapeutics|April 20, 2013
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphomaDongwei Li, Kirsten Achilles Poon, Shang-Fan Yu, et al.
Blood|March 26, 2013
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patientsAnnika Dufour, Giuseppe Palermo, Evelyn Zellmeier, et al.
Science Translational Medicine|March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphomaBart Burington, Peng Yue, Xiaoyan Shi, et al.
Blood|June 12, 2014
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemiaMartin Weisser, Ru-Fang Yeh, Guillemette Duchateau-Nguyen, et al.
Nature Cancer|February 5, 2022
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunityShelley E Ackerman, Cecelia I Pearson, Joshua D Gregorio, et al.
Cancer Discovery|November 5, 2017
<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor SpheroidsRussell W Jenkins, Amir R Aref, Patrick H Lizotte, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Blood|July 28, 2009
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphomaDavid Dornan, Fiona Bennett, Yvonne Chen, et al.
Science Signaling|June 16, 2011
TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Science Signaling|August 27, 2011
miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Blood|August 14, 2010
Effect of FCGR2A and FCGR3A variants on CLL outcomeDavid Dornan, Olivia Spleiss, Ru-Fang Yeh, et al.
Molecular Cancer Therapeutics|April 20, 2013
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphomaDongwei Li, Kirsten Achilles Poon, Shang-Fan Yu, et al.
Blood|March 26, 2013
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patientsAnnika Dufour, Giuseppe Palermo, Evelyn Zellmeier, et al.
Science Translational Medicine|March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphomaBart Burington, Peng Yue, Xiaoyan Shi, et al.
Blood|June 12, 2014
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemiaMartin Weisser, Ru-Fang Yeh, Guillemette Duchateau-Nguyen, et al.
Nature Cancer|February 5, 2022
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunityShelley E Ackerman, Cecelia I Pearson, Joshua D Gregorio, et al.
Cancer Discovery|November 5, 2017
<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor SpheroidsRussell W Jenkins, Amir R Aref, Patrick H Lizotte, et al.
Pageof 3